Oxaloacetate: Promising Bioenergetics, Unknown Long-Term Safety

Oxaloacetate is a Krebs cycle intermediate central to cellular energy production and the malate-aspartate shuttle. As a supplement (commonly sold as anhydrous enol-oxaloacetate, brand name benaGene), it has gained attention for putative effects on metabolic flexibility, longevity, mitochondrial function, and cognitive symptoms in long COVID and ME/CFS. Early data are interesting, the marketing has run far ahead of them, and the long-term safety profile is undefined.

Why bioenergetics researchers are interested

Supplemental oxaloacetate raises NAD+/NADH ratios and may shift cells toward states that mimic caloric restriction, including activation of FOXO transcription factors and SIRT1-related signalling [1]. In C. elegans, oxaloacetate extended lifespan by roughly 20% in some experiments [2]. Rodent studies show neuroprotective effects in models of stroke and Alzheimer's at doses around 1.5–4 g/kg/day, suggesting glutamate scavenging in cerebral spinal fluid as one mechanism [3].

What human data exists

Open-label and small randomised studies have explored 100–2,000 mg/day for fatigue and cognitive symptoms. A 2022 open-label study in long COVID patients reported subjective improvements in fatigue at 1,000 mg/day over six weeks [4]. A separate ME/CFS pilot reported similar findings [5]. There are no large, double-blind, placebo-controlled trials with hard endpoints. Effects on glucose, insulin sensitivity, or cognitive performance in healthy adults have not been demonstrated.

Safety considerations that aren't being discussed enough

Short-term tolerability in published trials looks acceptable: mild GI upset, occasional headache, no signal of liver or kidney toxicity in trials of weeks to a few months [6]. Important gaps: long-term effects on mitochondrial flux are unstudied; effects on patients with diabetes (where TCA cycle intermediates may interact with metformin and SGLT2 inhibitors) are unknown; effects in cancer (where altered metabolic shuttles can support tumour growth) are theoretically concerning and untested. Some preclinical work suggests oxaloacetate can fuel certain tumour types [7].

Quality and stability

Crystalline anhydrous oxaloacetate is unstable and hygroscopic, decomposing to pyruvate in solution. Most supplements are formulated with vitamin C as a stabiliser (typically 100 mg vitamin C per 100 mg oxaloacetate). Capsules should be kept dry and used before expiration; degraded product loses activity [8].

Drug and condition interactions to consider

Theoretical interactions exist with metformin, GLP-1 agonists, ketogenic diets, and oncology therapies. There are no published interaction studies, but the mechanistic plausibility means people on these therapies should not start oxaloacetate without specialist input. Pregnancy and lactation safety is undefined; do not use during these periods.

Practical takeaway

Oxaloacetate is a biologically credible, small-trial-supported option for adults with persistent post-viral or ME/CFS-type fatigue who have exhausted standard options and are working with a clinician. It should not be marketed or used as a longevity supplement, anti-cancer agent, or general energy booster. The evidence is too preliminary, the long-term safety too undefined, and the cost too high to justify casual use.

How oxaloacetate sits in the broader bioenergetics supplement landscape

Several supplements are marketed for "mitochondrial energy" — coenzyme Q10, PQQ, alpha-ketoglutarate, NAD precursors (NMN, NR), creatine, and oxaloacetate. They have very different evidence bases and mechanisms. Coenzyme Q10 has the most established role in primary mitochondrial disease and statin-related myopathy. Creatine has decades of data for muscle and emerging cognitive trials. NAD precursors raise blood NAD but have not shown clear functional benefits in healthy adults. Oxaloacetate is the newest entrant, with the smallest trial base, and the highest cost per dose.

Cost-benefit honesty

A typical 100 mg oxaloacetate capsule costs in the range of $1–2 per dose; the trial dose of 1,000 mg/day works out to several hundred dollars per month. Anyone considering it should weigh that cost against well-established interventions — adequate sleep, graded exercise (where tolerated), addressing iron and B12 deficiency, and managing post-exertional malaise — that have stronger evidence and lower cost. For people who have exhausted those interventions, a time-limited trial under clinician supervision is reasonable; long-term self-funded use is hard to justify on current data.